Johnson & Johnson (NYSE:JNJ) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. Cramer was quite bullish on the company’s stock, as he stated:

Yesterday, we got some terrific news from Johnson & Johnson, but because the tape was so ugly, the stock did nothing. Actually finished the session down 0.35%. Oh, it was a brutal session… Sometimes, a terrible, horrible, no good, very bad day for the averages creates buying opportunities for you, and I think we’re getting one right now in Johnson & Johnson. Why? Because yesterday morning, we learned that they got FDA approval for ICOTYDE. Now, that is their oral treatment for moderate to severe plaque psoriasis…

Photo by Artem Podrez on Pexels

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.